Market closedNon-fractionalADR
Zai Lab/ZLAB
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Zai Lab
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Ticker
ZLAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Shanghai, China
Employees
2,175
Website
www.zailaboratory.com
Zai Lab Metrics
BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$3.50
EPS
1.15
Beta
-
Dividend rate
Price and volume
Market cap
$1.9B
Beta
1.15
52-week high
$37.92
52-week low
$13.48
Average daily volume
14
Financial strength
Current ratio
4.626
Quick ratio
4.429
Total debt to equity
6.334
Management effectiveness
Return on assets (TTM)
-31.41%
Return on equity (TTM)
-38.44%
Return on investment (TTM)
-36.81%
Valuation
Price to revenue (TTM)
6.382
Price to book
2.271
Price to tangible book (TTM)
2.488
Growth
Revenue change (TTM)
25.94%
Earnings per share change (TTM)
18.15%
3-year revenue growth
75.96%
What the Analysts think about Zai Lab
Analyst Ratings
Majority rating from 11 analysts.
Zai Lab Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$87M
32.37%
Net income
-$53M
-44.03%
Profit margin
-61.30%
-57.72%
Zai Lab Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
-$0.71
-$1.00
-$0.50
-
Expected
-$0.79
-$1.04
-$0.86
-$0.92
-$0.77
Surprise
58.43%
-32.01%
16.82%
-45.94%
-
Zai Lab News
AllArticlesVideos
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Business Wire·3 weeks ago
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Business Wire·1 month ago
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $1.9B as of July 05, 2024.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of July 05, 2024.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Zai Lab stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.